IN2012DN03128A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03128A
IN2012DN03128A IN3128DEN2012A IN2012DN03128A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A IN 3128DEN2012 A IN3128DEN2012 A IN 3128DEN2012A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A
Authority
IN
India
Prior art keywords
compositions
eye
active ingredient
treatment
group
Prior art date
Application number
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Gunther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03128A publication Critical patent/IN2012DN03128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
IN3128DEN2012 2009-12-14 2010-12-13 IN2012DN03128A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
IN2012DN03128A true IN2012DN03128A (en) 2015-09-18

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3128DEN2012 IN2012DN03128A (en) 2009-12-14 2010-12-13

Country Status (15)

Country Link
US (1) US8614178B2 (en)
EP (2) EP2335735A1 (en)
JP (5) JP5663595B2 (en)
KR (2) KR101652714B1 (en)
CN (1) CN102652022B (en)
AU (1) AU2010333039B2 (en)
BR (3) BR112012014190B8 (en)
CA (2) CA2776860C (en)
DK (1) DK2512515T3 (en)
ES (1) ES2449308T3 (en)
IN (1) IN2012DN03128A (en)
MX (1) MX2012006720A (en)
PL (1) PL2512515T3 (en)
PT (1) PT2512515E (en)
WO (1) WO2011073134A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010256558B2 (en) 2009-06-03 2013-10-03 Forsight Labs, Llc Anterior segment drug delivery
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
ES2625538T3 (en) 2012-01-23 2017-07-19 Novaliq Gmbh Stabilized protein compositions based on semi-fluorinated alkanes
CN104619314B (en) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 Compositions comprising mixtures of semifluorinated alkanes
BR112015005008B1 (en) 2012-09-12 2022-04-19 Novaliq Gmbh Semifluorinated alkane compositions
EP2708228B1 (en) 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6304475B2 (en) * 2013-01-31 2018-04-04 ロート製薬株式会社 Eye drops
CN105073112B (en) 2013-03-13 2017-12-29 参天制药株式会社 Therapeutic agent for meibomian gland dysfunction
CN114028560A (en) * 2013-07-23 2022-02-11 诺瓦利克有限责任公司 Stabilized antibody compositions
CA2927321A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
CN113662929A (en) * 2015-09-30 2021-11-19 诺瓦利克有限责任公司 Semi-fluorinated compounds for ophthalmic administration
CN108348777B (en) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 Semifluorinated compounds and compositions thereof
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (en) 2016-09-22 2024-05-22 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
KR20190057338A (en) * 2016-09-23 2019-05-28 노바리크 게엠베하 An ophthalmic composition comprising a cyclosporin
BR112019006194A2 (en) * 2016-09-28 2019-06-18 Novaliq Gmbh compositions comprising a cannabinoid receptor binding binder
WO2018114557A1 (en) * 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
ES2819005T3 (en) * 2016-12-23 2021-04-14 Novaliq Gmbh Ophthalmic composition for the treatment of dry eye disease
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3612228B1 (en) * 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (en) 2017-09-27 2020-07-29 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF EYE DISEASES.
CN111182893A (en) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 Ophthalmic composition comprising F6H8
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical compositions containing timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
KR20210080388A (en) 2018-09-22 2021-06-30 노바리크 게엠베하 Ophthalmic composition for the treatment of ocular surface damage and dryness symptoms
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
CN112823020A (en) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 Ophthalmic compositions for treating dry eye
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020281641B2 (en) 2019-05-24 2025-09-11 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2024170514A1 (en) * 2023-02-13 2024-08-22 Novaliq Gmbh Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (en) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Composition of Eye Drop Cyclosporin
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (en) * 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
DE19861012A1 (en) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease
CN1190194C (en) * 1999-04-30 2005-02-23 苏坎波公司 Use of macrolide compounds for treatment of dry eye
DE19938668B4 (en) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Artificial tears
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
ES2387619T3 (en) * 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Pulmonary Surfactant Supplements
JP2008501806A (en) * 2004-06-08 2008-01-24 オキュラリス ファーマ， インコーポレイテッド Hydrophobic ophthalmic composition and method of use
DE102007055046A1 (en) * 2007-11-19 2009-05-28 Fluoron Gmbh infusion
EP2110126B9 (en) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative and instillative use of semi-fluorised alkanes as active ingredient carriers in the intrapulmonary area

Also Published As

Publication number Publication date
JP6731039B2 (en) 2020-07-29
JP2017078086A (en) 2017-04-27
EP2335735A1 (en) 2011-06-22
EP2512515B1 (en) 2013-12-25
CN102652022A (en) 2012-08-29
HK1172269A1 (en) 2013-04-19
US20120244177A1 (en) 2012-09-27
JP2015028064A (en) 2015-02-12
EP2512515A1 (en) 2012-10-24
BR122020020872B1 (en) 2021-09-08
US8614178B2 (en) 2013-12-24
KR101722039B1 (en) 2017-03-31
KR20160105533A (en) 2016-09-06
BR112012014190A2 (en) 2016-05-31
MX2012006720A (en) 2012-07-30
CN102652022B (en) 2014-12-17
CA2776860C (en) 2016-10-25
BR122017018955B1 (en) 2022-03-08
JP2013513586A (en) 2013-04-22
PT2512515E (en) 2014-03-04
CA2941956C (en) 2018-09-04
BR112012014190B8 (en) 2021-05-25
CA2776860A1 (en) 2011-06-23
DK2512515T3 (en) 2014-03-10
CA2941956A1 (en) 2011-06-23
AU2010333039B2 (en) 2014-08-28
JP5663595B2 (en) 2015-02-04
JP2019006803A (en) 2019-01-17
AU2010333039A1 (en) 2012-07-12
KR101652714B1 (en) 2016-09-01
ES2449308T3 (en) 2014-03-19
JP2019070003A (en) 2019-05-09
JP6397472B2 (en) 2018-09-26
KR20120115977A (en) 2012-10-19
WO2011073134A1 (en) 2011-06-23
JP6096731B2 (en) 2017-03-15
BR112012014190B1 (en) 2021-03-02
PL2512515T3 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
MX2012006720A (en) Pharmaceutical composition for treatment of dry eye syndrome.
MX389597B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
WO2014047427A3 (en) Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
NZ708593A (en) Novel pyrazole derivative
PH12014500943A1 (en) Combination treatment of cancer
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
EP4292662A3 (en) Substituted indole mcl-1 inhibitors
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CU20160109A7 (en) INDAZOL COMPOUNDS AS IRAK4 INHIBITORS
MX2016011468A (en) Human plasma kallikrein inhibitors.
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
DOP2019000275A (en) NEW BICYCLIC PIRAZOLE DERIVATIVES
EP4403552A3 (en) C-terminal hsp90-inhibitors
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
EP4414376A3 (en) Novel depsipeptide and uses thereof
CO6602152A2 (en) In response to the request for payment of additional claims to the first 10, it presents a new claim chapter and pays.
EP3216798A3 (en) Ketolide compounds
MX341220B (en) Tamarind seed polysaccharide for use in the treatment of microbial infections.
EP4299126A3 (en) Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
CL2012003521A1 (en) Piperidino derivative (r) -n - ((r) -1 - ((3s-4s) -4- (4-chlorophenyl) -3,4-dihydroxy-3-methylpiperidin-1-yl) -3-methyl-1 -oxobutan-2-yl) -3,3-difluorocyclopentanecarboxamide, chemokine receptor modulator; pharmaceutical composition; and use of the compound and its composition in inflammatory and autoimmune diseases, among others.
MX2024010625A (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof.
MX2020012989A (en) Therapeutic agent for fibrosis.
IN2014CN02908A (en)
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators